Drug rechallenge following drug‐induced liver injury

Christine M. Hunt, Julie I. Papay, Vid Stanulovic, Arie Regev – 13 March 2017 – Drug‐induced hepatocellular injury is identified internationally by alanine aminotransferase (ALT) levels equal to or exceeding 5× the upper limit of normal (ULN) appearing within 3 months of drug initiation, after alternative causes are excluded. Upon withdrawing the suspect drug, ALT generally decrease by 50% or more. With drug readministration, a positive rechallenge has recently been defined by an ALT level of 3‐5× ULN or greater.

Regression of hepatocellular adenomas and systemic inflammatory syndrome after cessation of estrogen therapy

Marie Sinclair, Anthony Schelleman, Daljean Sandhu, Peter W. Angus – 13 March 2017 – We report a case of dramatic systemic inflammatory symptoms and biochemical signs of inflammation related to multiple hepatic adenomas that completely resolved after cessation of the oral contraceptive pill (OCP) and associated adenoma regression. This represents a case of dramatic symptoms that resolved after estrogen withdrawal alone. (Hepatology 2017;66:989–991).

Immune phenotype and function of natural killer and T cells in chronic hepatitis C patients who received a single dose of anti‐MicroRNA‐122, RG‐101

Femke Stelma, Meike H. van der Ree, Marjan J. Sinnige, Anthony Brown, Leo Swadling, J. Marleen L. de Vree, Sophie B. Willemse, Marc van der Valk, Paul Grint, Steven Neben, Paul Klenerman, Eleanor Barnes, Neeltje A. Kootstra, Hendrik W. Reesink – 11 March 2017 – MicroRNA‐122 is an important host factor for the hepatitis C virus (HCV). Treatment with RG‐101, an N‐acetylgalactosamine‐conjugated anti‐microRNA‐122 oligonucleotide, resulted in a significant viral load reduction in patients with chronic HCV infection. Here, we analyzed the effects of RG‐101 therapy on antiviral immunity.

Ethanol exposure inhibits hepatocyte lipophagy by inactivating the small guanosine triphosphatase Rab7

Ryan J. Schulze, Karuna Rasineni, Shaun G. Weller, Micah B. Schott, Barbara Schroeder, Carol A. Casey, Mark A. McNiven – 10 March 2017 – Alcohol consumption is a well‐established risk factor for the onset and progression of fatty liver disease. An estimated 90% of heavy drinkers are thought to develop significant liver steatosis. For these reasons, an increased understanding of the molecular basis for alcohol‐induced hepatic steatosis is important.

Resistance mutations of hepatitis B virus in entecavir‐refractory patients

Norie Yamada, Ryuichi Sugiyama, Sayuri Nitta, Asako Murayama, Minoru Kobayashi, Chiaki Okuse, Michihiro Suzuki, Kiyomi Yasuda, Hiroshi Yotsuyanagi, Kyoji Moriya, Kazuhiko Koike, Takaji Wakita, Takanobu Kato – 9 March 2017 – The emergence of resistance mutations in the reverse transcriptase gene of hepatitis B virus (HBV) is associated with treatment failure. Entecavir (ETV) is one of the most potent anti‐HBV reagents; it has a very low resistance rate and is used as the first‐line treatment for chronic hepatitis B.

LiverLearning®: 2017 Webinar: Controversy Regarding HCV Treatment and HCC Recurrence

This webinar will review this latest controversy regarding the increased risk of hepatocellular carcinoma recurrence in patients receiving direct acting antiviral agents for the treatment of HCV. Recent studies have suggested that HCC recurrence is increased in HCV patients receiving direct antiviral agents.Michael D. Leise (Moderator) Dr.

The animal naming test: An easy tool for the assessment of hepatic encephalopathy

Francesca Campagna, Sara Montagnese, Lorenzo Ridola, Marco Senzolo, Sami Schiff, Michele De Rui, Chiara Pasquale, Silvia Nardelli, Ilaria Pentassuglio, Carlo Merkel, Paolo Angeli, Oliviero Riggio, Piero Amodio – 8 March 2017 – Screening for hepatic encephalopathy (HE) that does not cause obvious disorientation or asterixis (minimal HE [MHE]/grade 1 HE) is important. We examined if the animal naming test (ANT1) (maximum number of animals listed in 1 minute) is useful in this context.

The role of long noncoding RNA H19 in gender disparity of cholestatic liver injury in multidrug resistance 2 gene knockout mice

Xiaojiaoyang Li, Runping Liu, Jing Yang, Lixin Sun, Luyong Zhang, Zhenzhou Jiang, Puneet Puri, Emily C. Gurley, Guanhua Lai, Yuping Tang, Zhiming Huang, William M. Pandak, Phillip B. Hylemon, Huiping Zhou – 8 March 2017 – The multidrug resistance 2 knockout (Mdr2–/–) mouse is a well‐established model of cholestatic cholangiopathies. Female Mdr2–/– mice develop more severe hepatobiliary damage than male Mdr2–/– mice, which is correlated with a higher proportion of taurocholate in the bile.

Subscribe to